Create a Website Account - Manage notification subscriptions, save form progress and more.
March 15, 2023
On December 29, 2022, the Substance Abuse and Mental Health Services Administration (SAMHSA) and the Drug Enforcement Agency (DEA) eliminated the requirement for providers to have a DATA 2000 (X) waiver to prescribe buprenorphine containing medication products for the treatment of opioid use disorder. SAMHSA has additionally removed the limit on the number of patients a provider can prescribe buprenorphine medications to. The goal of this is to reduce prescribing barriers for providers and increase access to life saving medication assisted treatment with buprenorphine for people seeking treatment for opioid use disorder (OUD).
If you have not prescribed buprenorphine or Suboxone® (buprenorphine/naloxone) and would like additional education, there are many resources available to support safe and effective treatment of opioid use disorder.
This health advisory adapted from the Washington State Department of Health.